Magnetic brain zap reveals clues to bipolar mood swings
NCT ID NCT04696471
First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This study used a non-invasive brain stimulation technique called theta burst stimulation (TMS) to explore how the brain processes rewards in people with bipolar disorder. Researchers compared brain scans before and after stimulation in 146 adults, both with and without bipolar disorder, while they played a reward-based game. The goal was to identify brain activity patterns linked to mood swings, which could lead to better understanding and future treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Continuous Theta Burst Stimulation (cTBS) via Transcranial Magnetic Stimulation (TMS)
- What this could lead to
- If successful, this research could help explain the brain mechanisms behind mood swings in bipolar disorder, potentially pointing toward new treatment targets.
- What could go wrong
- This is an early-stage, completed study focused on understanding brain activity, not testing a treatment. The results may not directly lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
146 people
The number who actually took part.
- Started
-
Apr 2021
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. All participants * 18-35 years of age * Scoring less than or equal to 8 on the Hamilton Rating Scale for Depression (HRSD) at screen visit 2. Participants with Bipolar Disorder (BD) * Diagnosis of Bipolar Disorder I/II (BDI/II) (DSM-5 criteria) in remission (euthymic for \>2 months) or with mild-moderate hypomania * \<15 on the Young Mania Rating Scale * Not psychotic * \<3 on delusions, hallucinations, unusual thought content, and conceptual disorganization items of the Positive and Negative Syndrome Scale (PANSS) * Unmedicated or on any combination (except antidepressant monotherapy) of anxiolytics (benzodiazepines, buspirone, pregabalin, hydroxyzine) as needed, and/or atypical antipsychotics, and/or lithium, and/or other mood stabilizers, and/or non-SNRI antidepressants and/or non benzodiazepine hypnotics, as these are commonly-prescribed medications for BD 3. Participants without Bipolar Disorder * No present or lifetime history of BD or psychiatric disorder other than anxiety or non BD mood disorders * Not in a current depressive episode * No family history of BD Exclusion Criteria: 1. All participants * History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report) * Family history of epilepsy (TBS exclusion criterion) * Use of substances with seizure risk (e.g., stimulants) in the past month, assessed as at screening, baseline, and before each fMRI-cTBS-fMRI session * Mini-Mental State Examination score (cognitive state) \<24 * Premorbid National Adult Reading Test Intelligent Quotient estimate\<85 * Visual disturbance: \<20/40 Snellen visual acuity * Left/mixed handedness * History of alcohol/substance use disorder (SUD; all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (SCID-5). Note: lifetime/present cannabis use (at non-abuse (\<3 times in the past month) and non SUD levels) will be allowed, given its common usage in BD and young adults. Cannabis SUD over the last 6 months will not be allowed. Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals * Binge drinking in the week before, and/or \>3 units/day for the 3 days before, and/or alcohol in the last 12 hrs before, any cTBS scan day, confirmed at screening and scan days (to avoid TBS during alcohol withdrawal). Alcohol/nicotine/ caffeine/cannabis use (below SCID-5 SUD, binge levels) will be allowed, and used as covariates * MRI exclusion criteria: metallic objects, e.g., surgical implants; claustrophobia; proneness; positive pregnancy test for females (performed at the MRRC) or self-report pregnancy * Inability to understand English * \<18 years of age or \>35 year of age * SNRI antidepressants and bupropion will not be allowed, as they can elevate seizure risk, a contraindication for TBS * Scoring greater than or equal to 8 on HRSD and in depressive episode is confirmed on SCID-5 at screen visit * Scoring greater than or equal to 18 on HRSD at any visit * In current depressive episode 2. Participants with Bipolar Disorder * BD diagnosis other than BDI/II * More severe hypo/mania (YMRS\>15) * Psychosis * Using psychotropic medications other than those allowed in inclusion criteria 3. Participants without Bipolar Disorder * Present/ lifetime history of any psychiatric disorder other than anxiety and non BD mood disorders * Family history of of BD
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five sessions to quiet trauma nightmares in bipolar disorder
- Sound waves vs. depression: can focused ultrasound lift mood?
- Can a nasal insulin spray rev up brain energy and sharpen thinking in psychosis?
- Smartphone sensors may predict bipolar mood swings before they strike
- Could immune cells hold clues to bipolar disorder?
- Can a 6,000-Person study unlock personalized depression care for asians?